Previous Article | Next Article 
Journal of Virology, June 2000, p. 5310-5319, Vol. 74, No. 11
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Mutation of a Conserved Residue (D123) Required for
Oligomerization of Human Immunodeficiency Virus Type 1 Nef Protein
Abolishes Interaction with Human Thioesterase and Results in
Impairment of Nef Biological Functions
Lang Xia
Liu,1
Nikolaus
Heveker,2
Oliver T.
Fackler,3
Stefan
Arold,4
Sylvie
Le
Gall,5
Katy
Janvier,1
B. Matija
Peterlin,3
Christian
Dumas,4
Olivier
Schwartz,5
Serge
Benichou,1 and
Richard
Benarous1,*
Institut Cochin de Génétique
Moléculaire, INSERM U 529 Université Paris
V,1 and INSERM U
332,2 75014 Paris, Centre de Biochimie
Structurale, UMR 9955 CNRS U414 INSERM, 34060 Montpellier,4 and Laboratoire
Rétrovirus et Transfert Génétique, URA CNRS 1157,
Institut Pasteur, 75724 Paris Cedex 15,5
France, and Howard Hughes Medical Institute and Departments
of Medicine, Microbiology, and Immunology, University of California
at San Francisco, San Francisco, California
94143-07033
Received 24 November 1999/Accepted 2 March 2000
 |
ABSTRACT |
Nef is a myristoylated protein of 27 to 35 kDa that is conserved in
primate lentiviruses. In vivo, Nef is required for high viral load and
full pathological effects. In vitro, Nef has at least four activities:
induction of CD4 and major histocompatibility complex (MHC) class I
downregulation, enhancement of viral infectivity, and alteration of
T-cell activation pathways. We previously reported that the Nef protein
from human immunodeficiency virus type 1 interacts with a novel
human thioesterase (hTE). In the present study, by mutational analysis,
we identified a region of the Nef core, extending from the residues
D108 to W124, that is involved both in Nef-hTE interaction and in
Nef-induced CD4 downregulation. This region of Nef is located on the
oligomer interface and is in close proximity to the putative CD4
binding site. One of the mutants carrying a mutation in this region,
targeted to the conserved residue D123, was also found to be defective
in two other functions of Nef, MHC class I downmodulation and
enhancement of viral infectivity. Furthermore, mutation of this residue
affected the ability of Nef to form dimers, suggesting that the
oligomerization of Nef may be critical for its multiple functions.
 |
INTRODUCTION |
The nef gene of the
primate lentiviruses encodes a 27-kDa protein anchored at the
cytoplasmic face of the plasma membrane through a myristate at its
amino terminus (for reviews, see references 13 and
37). Experiments in rhesus monkeys infected with
simian immunodeficiency virus (SIV) strain SIVmac with a disrupted
nef gene have demonstrated the importance of the Nef protein
for maintenance of high virus loads and disease progression
(30).
In vitro studies revealed that Nef downregulates both CD4 and major
histocompatibility complex class I (MHC-I) cell surface expression,
which may contribute to the preservation of viral infectivity and
immune evasion, respectively (for a review, see reference
46). These two activities mainly result from
Nef-induced CD4- and MHC-I-accelerated endocytosis, involving a
dileucine sequence and a Tyr-based motif located in the cytoplasmic
domains of CD4 and MHC-1, respectively. However, the mechanisms by
which Nef downregulates CD4 and MHC-I have not yet been fully
elucidated. Whereas Nef could act as a physical connector between CD4
and the cellular endocytotic pathway, it may rather reveal a cryptic endocytosis motif in MHC-I (34, 38; for a review,
see reference 47).
In addition to the induction of CD4 and MHC-I downregulation, Nef
enhances virus infectivity. At least two mechanisms could account for
this activity. First, Nef stimulates viral infectivity in a
CD4-independent manner. This effect could be the consequence of
stimulation of proviral DNA synthesis. Nef might also facilitate phosphorylation of the matrix protein by a cellular protein kinase required for the maintenance of optimal virion infectivity
(58, 60). Second, Nef may counteract, by downregulating CD4,
the inhibitory effect of CD4 on envelope virion incorporation and function (48, 50; for reviews, see references
26 and 32). Conflicting results
concerning the effects of Nef on the T-cell activation pathways have
been reported, depending on its intracellular localization (5, 10,
15, 57).
In order to elucidate the mechanisms of Nef actions, attempts have been
made to identify the cellular mediators and the regions required for
its functions. Nef has been shown to interact with various cellular
proteins, including CD4 (26, 51),
-COP (6, 46), human thioesterase (hTE) (35), the µ1 and µ2
chains of clathrin adaptor protein (AP) complexes (34, 58),
Hck (42, 52), Lck protein tyrosine kinase (10,
21), and serine threonine kinases (4, 43, 53). More
recently, it has been shown that Nef proteins from SIV and human
immunodeficiency virus (HIV) interact with the T-cell receptor
chain (28, 61). This interaction is involved in the HIV-1
Nef-induced upregulation of Fas ligand (61). Nef also
interacts with a guanine nucleotide exchange factor, Vav, and leads to
increased activity of Vav and its downstream effectors, such as
cytoskeletal changes and the activation of c-Jun N-terminal kinase
(17).
Although membrane localization through myristoylation is required for
all Nef functions (1, 19, 54), different regions of Nef have
been implicated in CD4 and MHC-I downregulation and in enhancement of
viral infectivity. It has been reported that the proline-rich
SH3-binding region of HIV-1 Nef (PxxP, residues 72 to 77) is implicated
in the enhancement of virion infectivity and in MHC-I downregulation
but not in CD4 downregulation (21, 39, 52). However, a
recent study showed that this motif also contributed to CD4
downregulation and that this effect could be observed only when Nef was
expressed at low levels (12). In addition, a dileucine-based
protein sorting motif in Nef has been shown to be required for CD4
downregulation and optimal viral infectivity but not for downregulation
of MHC-I (11, 12). Structural and biochemical studies
indicated that Nef might form oligomers (2, 16, 31).
However, the functional significance of Nef oligomerization remains unknown.
We reported that Nef proteins from various HIV-1 isolates interact with
a novel hTE homologous to the thioesterase II of Escherichia coli (35). We found that a Nef mutant generated by
random mutagenesis and mutated in several amino acid residues, which
had lost the ability to interact with hTE, was also defective for CD4
downregulation activity (35). In the present work, using
site-directed mutagenesis, we demonstrate that mutations in a region of
the Nef core extending from residues D108 to W124 abolish both Nef-hTE
interaction and CD4 downregulation. One of these mutants carrying a
mutation targeted to the conserved residue D123 was also defective for
MHC-I downmodulation and enhancement of viral infectivity. Furthermore,
mutation of this residue resulted in the impairment of Nef oligomerization.
 |
MATERIALS AND METHODS |
Plasmid constructions and generation of Nef mutants.
A
PCR-generated BamHI-SalI fragment corresponding
to the coding sequence of the Nef protein from isolate HIV-1Lai was
cloned into the pcDNA3 mammalian expression vector (Invitrogen) by
insertion at the BamHI and XhoI sites, resulting
in construct pcDNA3-NefLai. NefLai mutants were generated by PCR with
pfu polymerase (Stratagene) and appropriate primers as
described by Chowers et al. (8). The resulting amplified
products were then purified and inserted in various expression vectors.
All inserts were entirely sequenced using an automated ABI sequencer to
check that the desired mutants had been obtained. The
XhoI-PmlI fragments of the Nef4 and NefD123G mutants, which contain corresponding mutations, were inserted into a
proviral infectious HIV-1 NL4-3-derived clone containing a unique
PmlI site (52).
Two-hybrid assays.
The PCR fragments corresponding to
different Nef mutants, generated as described above, were inserted into
the yeast expression vector pGBT10 by using the restriction sites
BamHI at the 5' end and SalI at the 3' end to
fuse these Nef mutants in frame with the GAL4 binding domain (Gal4BD).
The resulting constructs were cotransformed into yeast strain HF7c with
vector pGAD1318, expressing hTE in fusion with the Gal4 activation
domain (Gal4AD), as previously described (6, 34, 35).
-Galactosidase quantitative assays were performed with strain SFY526
as described previously (7). Assays were performed in duplicate.
CD4 downregulation assay.
A 10-µg amount of pcDNA3 vector
carrying wild-type or mutated Nef sequences was cotransfected into P4-2
cells (HeLa CD4+ cells expressing
-galactosidase under
the control of the HIV-1 LTR) (9) with 2 µg of pcDNA3-GFP
(expressing green fluorescent protein [GFP]) by electroporation as
previously described (34). Briefly, P4-2 cells (8 × 106 cells per point) resuspended in 200 µl of Dulbecco's
modified Eagle's medium with 10% fetal calf serum and 10 mM HEPES
were mixed with 50 µl of 200 mM NaCl containing the appropriate
plasmids. Electroporation was performed at 200 V and 960 µF in
4-mm-wide cuvettes in a Bio-Rad Gene Pulser. At 24 h after
transfection, cells were labeled with phycoerythrin-conjugated anti-CD4
monoclonal antibodies (Leu3A; Becton Dickinson) as described previously
(55). The surface expression of CD4 was analyzed on
GFP-positive cells with a FACScan cytofluorimeter (Becton Dickinson).
MHC-I downregulation assay.
The Nef-FT vector carrying the
NefLai coding sequence is a gift from F. Bachelerie (Institut Pasteur,
Paris, France) (3). The Nef-FT-D123G vector was constructed
by replacing the BlpI-BspEI fragment in the
NefLai coding sequence of the Nef-FT vector with the corresponding
BlpI-BspEI fragment of the PCR product containing the mutation D123G. The HLA-A2 vector was a kind gift from F. Lemonnier
(Institut Pasteur, Paris, France). The HLA-A2 gene was subcloned in a pcDNA plasmid (Biolabs), yielding pCA2. pCA2 (4 µg)
and pCDNA3-GFP (2 µg) were cotransfected into HeLa cells together with either 12 µg of Nef-FT, Nef-FT-D123G, or Nef-mock plasmid. The
cellular surface expression level of the HLA-A2 allele on GFP-positive cells was analyzed with anti-HLA-A2 BB7.2 antibodies by
flow cytometry as previously described (55).
Virus production and infectivity assay.
Infectious viruses
were prepared from the supernatant of HeLa cells transfected with
proviral DNA. Cells transfected by the calcium phosphate method were
washed 24 h posttransfection, and infectious supernatant was
collected after a further 24 h, filtered through a
0.45-µm-pore-size filter, and used immediately for infection assays.
The p24 content in supernatant aliquots was simultaneously quantified
using a commercial test kit (p24-ELISA; Innogenetics, Ghent, Belgium).
Viral infectivity was determined by incubating different dilutions of
supernatants on semiconfluent HeLa-P4 indicator cells in six-well
plates in a final volume of 2 ml. After 24 h, the cells were fixed
in 0.5% glutaraldehyde, and infected cells were stained blue with
X-Gal (5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) substrate as described before (14). Blue cells were scored
from randomly selected fields under 40× magnification, and the total number of infected cells per well was calculated and correlated with
the amount of input p24.
Assay for oligomerization of Nef.
A plasmid encoding hybrid
Nef protein fused to the extracellular and transmembrane domain
of CD8 (CD8Nefwt) was constructed as previously described
(17). The mutation D123V was introduced into the CD8Nef
construct by PCR-mediated mutagenesis, resulting in CD8NefD123V.
The truncated protein CD8T, which contained only the extracellular and
transmembrane domains of CD8 with no intracellular residues
(17), was used as a control. 293T cells were transfected with CD8T, CD8Nefwt, or CD8NefD123V by using lipofectamine
(Gibco) according to the manufacturer's instructions. Cells were
harvested at 48 h posttransfection, lysed in kinase extraction
buffer (17), and analyzed by Western blotting. For the
visualization of Nef homodimers, membranes were probed with the
anti-Nef monoclonal antibody 158 (16).
Immunoblot analyses.
Transfected or infected cells were
lysed in 25 mM HEPES (pH 7.4)-150 mM KCl-5 mM EDTA-1% Triton X-100
at 4°C for 30 min. After centrifugation at 13,000 × g for 5 min, the clarified supernatant containing cellular lysates
from about 600,000 transfected or infected cells was electrophoresed on
sodium dodecyl sulfate-12% polyacrylamide gel electrophoresis
(SDS-PAGE) followed by electrophoretic transfer onto nitrocellulose
membranes as previously described (35). Immunoblot analyses
of Nef were performed with either an anti-HIV-1BH10 Nef antiserum
(1:2,000) (National Institutes of Health AIDS repository, catalog no.
2121) (see Fig. 2E) or an anti-HIV-1Lai antiserum (1:1,000) (see Fig.
5B), raised in rabbits by immunization with the fused protein
glutathione-S-transferase (GST)-NefLai (N. Heveker,
unpublished results), and then developed by the enhanced
chemiluminescence system (Amersham Pharmacia Biotech).
 |
RESULTS |
D123G mutation in HIV-1 Nef abolishes the ability of the protein to
interact with hTE and to downregulate CD4 cell surface expression.
A Nef mutant (Nef4) was previously isolated from a random Nef mutant
library generated by PCR mutagenesis on the basis of its lack of
interaction with hTE (35). This mutant contained five
substitutions, W57R, F68S, D123G, H166R, and L170Q, and was found to be
defective for CD4 downregulation. In order to determine which of these
mutations was responsible for the loss of Nef-hTE interaction and CD4
downregulation, we generated the corresponding Nef single mutants, each
containing one of these five mutations. These mutants were then fused
to the Gal4BD for hTE-binding analysis in a two-hybrid quantitative
assay and were expressed in HeLa CD4+ cells to determine
their ability to downregulate CD4 surface expression in a
transient-transfection assay. As shown in Fig. 1A, the two-hybrid assays revealed that
the single mutation D123G was sufficient to abolish Nef association
with hTE. Another substitution of the D123 residue, the D123V mutation,
gave identical results (data not shown), further demonstrating that the
D123 residue is required for interaction of Nef with hTE. The binding
of hTE to NefW57R was reduced to about 58% of that of wild-type Nef, whereas the three other mutations (NefF68S, NefH166R, and
NefL170Q) had no effect on hTE binding. Since the D123 residue is
located in a loop exposed on the surface of the protein (2, 23,
32), mutation of this residue is not predicted to significantly
alter the three-dimensional structure of the Nef core domain. This is consistent with our observation that mutation of the D123 residue did
not affect the interaction of Nef with other cellular partners, such as
the Hck SH3 domain, the µ1 chain of the AP1 adaptor complex, and
-COP (data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
D123G mutation in NefLai abolishes interaction of Nef
with hTE and Nef-induced CD4 downregulation. Five single mutants
containing each of the five mutations found in the Nef4 multiple mutant
were analyzed for hTE binding and for CD4 downregulation. (A)
Quantitative -galactosidase ( -gal) assays of wild-type Nef and
Nef mutants binding to hTE. Strain SFY526 expressing both hTE fused to
Gal4AD and wild-type Nef or Nef mutants fused to Gal4BD was assayed by
a -galactosidase assay. The results are expressed as
-galactosidase activity units determined for each wild-type or
mutated Nef protein (indicated in parentheses). The background level is
approximately 2 U and corresponds to SFY526 expressing both
Gal4BD-Nefwt and Gal4-AD-SNF4 hybrids (not shown). (B and C)
CD4 downregulation activity of Nef mutants. Wild-type and mutant Nef
proteins were transiently expressed in HeLa CD4+ P4-2 cells
in combination with GFP as described in the text. Surface levels of CD4
antigen were evaluated on GFP-positive cells by flow cytometry and are
represented by different colored areas as indicated. The control was
cells transfected with an empty pcDNA3 vector. Data are representative
of three independent experiments. (D) Expression levels of Nef mutants
in transfected cells used in the CD4 downregulation assays.
Immunoblotting of a total cell lysate with anti-Nef antibodies. Cells
were transfected with empty or recombinant expression vectors as
follows: pcDNA3 vector (lane 1), pcDNA3-Nefwt (lane 2),
pcDNA3-Nef4 (lane 3), pcDNA3-NefW57R (lane 4), pcDNA3-NefF68S (lane 5),
pcDNA3-NefD123G (lane 6), pcDNA3-NefH166R (lane 7), and pcDNA3-NefL170Q
(lane 8).
|
|
Flow cytometry analysis performed in P4-2 cells transiently transfected
with these Nef mutants showed that NefW57R and NefD123G (Fig. 1B) were
unable, like the Nef4 mutant, to downmodulate CD4 expression at the
cell surface, whereas the three other mutants, NefF68S, NefH166R, and
NefL170Q, were still fully or partially active (Fig. 1C, pink, light
blue, and yellow areas, respectively). As judged from immunoblotting,
the expression of wild-type and mutated Nef proteins in transfected
cells was comparable except for the mutant NefW57R which displayed a
lower expression level than the wild-type Nef protein (Fig. 1D). These
results indicate that the residue D123 in HIV-1Lai Nef is critical for
both Nef-hTE binding and Nef-induced CD4 downregulation, whereas the
inability of the NefW57R mutant to downregulate CD4 could be due to its instability.
Region extending from D108 to W124 of HIV-1 Nef is critical for
both hTE binding and CD4 downregulation.
The D123 residue,
together with most of the contiguous residues from D108 to N126, is
highly conserved in Nef proteins from many HIV-1 isolates
(56). Furthermore, several Nef multiple mutants that we
selected for lack of hTE binding in the two-hybrid assay contain
mutations in this region (L. X. Liu and R. Benarous, unpublished
results), suggesting that this region might be important for Nef
functions. To test this hypothesis, different Nef point mutants
containing various substitutions in this region have been generated (Fig. 2). The NefD108A,
NefD111G, NefW124R, and NefN126S mutants were generated based on the
mutations found in different Nef multiple mutants selected for the loss
of hTE binding in a two-hybrid assay (unpublished data). The NefL112D,
NefF121G, and NefP122R mutants (kind gift from George Cohen,
Massachusetts Institute of Technology) were selected from a library of
Nef single mutants randomly generated at defined residues. These Nef
mutants were analyzed first in a two-hybrid assay for interaction with
hTE and then in a transient-transfection assay for CD4 downregulation. As shown in Fig. 2, all of these mutants except N126S did not interact
with hTE, as indicated by the absence of
-galactosidase activity in
two-hybrid quantitative assays. Accordingly, all hTE-binding-deficient mutants were also deficient for CD4 downregulation (Fig.
3A), although they were expressed at a
level comparable to the wild-type Nef protein (Fig. 3B). In contrast,
mutant N126S was nearly as efficient as Nef wild-type protein in
inducing CD4 downregulation (Fig. 3A). These results clearly
demonstrate that there is a tight correlation between the ability of
Nef to interact with hTE and to mediate CD4 downregulation.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Two-hybrid assays of hTE binding to wild-type and mutant
Nef. The amino acid substitution in each Nef mutant is indicated at the
corresponding position of the delineated sequence between residues D108
and N126. hTE binding of wild-type and mutant Nef proteins was
determined as described in the legend to Fig. 1A. The percentage of
wild-type activity is shown in parentheses.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
CD4 downregulation activity of Nef mutants. (A) Analysis
of CD4 downregulation activity. HeLa P4-2 cells were transfected with
wild-type Nef, mutant Nef, or empty pcDNA3 (control) vector, along with
the pcDNA3-GFP vector. Surface expression of CD4 was analyzed on
GFP-positive cells by flow cytometry. Data are representative of three
independent experiments. (B) Expression levels of Nef mutants in the
transfected cells used in the CD4 downregulation assay, estimated by
immunoblotting of total cell lysates with anti-Nef antibodies.
|
|
NefD123G mutant fails to induce cell surface MHC-I
downregulation.
We then analyzed whether the D123G mutation
also affected Nef-dependent MHC-I downregulation. The NefD123G mutant,
wild-type NefLai, and an antisense Nef sequence were cloned into
the pCMV expression vector, resulting in the Nef-FT-D123G, Nef-FT, and Nef-mock constructs, respectively. Each of these constructs was then
cotransfected into P4-2 cells with the pCA2 construct, which allowed
expression of the HLA-A2 allele of MHC-I. HLA-A2 surface expression was analyzed by flow cytometry with the anti-HLA-A2 monoclonal antibody BB7.2 (34, 55). As shown in Fig.
4, HLA-A2 surface expression was reduced
in cells transfected with Nef-FT compared with cells transfected with
the Nef-mock construct. In the cells transfected with the Nef-FT-D123G
construct, no downregulation of HLA-A2 was observed, although the
expression levels of wild-type Nef and the NefD123G mutant were
comparable (data not shown). Therefore, the D123 residue is important
for both CD4 and MHC-I downregulation. In contrast, some other
mutations in this region (D108A and L112D), although causing deficient
CD4 downregulation (Fig. 3A), conserved the ability to downregulate
HLA-A2 (G. Cohen, personal communication), confirming that different
residues of the protein are involved in these two activities of Nef.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 4.
Mutation D123G in NefLai abolishes the ability of the
protein to downregulate MHC-I. HeLa P4-2 cells were transfected with
wild-type Nef-FT (green curve), mutant Nef-FT-D123G (pink dotted
curve), or Nef-mock (black curve) vector, along with the pCA
(HLA-A2) and pcDNA3-GFP vectors. Surface expression of
HLA-A2 was analyzed on GFP-positive cells with anti-HLA-A2 BB7.2
antibodies by flow cytometry. Data are representative of three
independent experiments.
|
|
NefD123G mutant also defective for Nef-induced enhancement of viral
infectivity.
Previous studies suggested that Nef-induced CD4
downregulation and enhancement of viral infectivity are independent
activities which rely on different structural domains of Nef
(19, 52, 54, 60). To determine whether the D123G mutation
affects the ability of Nef to enhance viral infectivity, the Nef4 and
NefD123G mutants were cloned into the infectious NL4-3 HIV-1 strain. As a negative control, we used an HIV-1 NL4-3 proviral clone carrying a
frameshift in the nef coding region (41, 52).
These proviral clones were transfected into HeLa cells to produce
infectious viruses. At 48 h after transfection, viral supernatants
were used to infect P4-2 (HeLa CD4+) cells. The infectivity
of these viral preparations was analyzed by counting the number of
infected blue cells with respect to the amounts of p24 antigen found in
the viral supernatant. As shown in Fig.
5A, the infectivity obtained with the
NL4-3 virus harboring wild-type Nef was about three times higher than
that obtained with the Nef-minus virus. The infectivity of the viruses harboring the Nef4 or NefD123G mutant was equivalent to that obtained with the Nef-minus virus (Fig. 5A), indicating that the single point
mutant NefD123G was also deficient for Nef-induced enhancement of
infectivity. The expression level of the wild-type and mutated Nef
proteins in cells producing virions was comparable, as shown by
immunoblotting with anti-Nef antibodies (Fig. 5B). By contrast, the
mutant D108A, deficient in hTE binding (Fig. 2) and CD4 downregulation (Fig. 3), conserved a significant ability to enhance virion infectivity (G. Cohen, personal communication). Altogether, these results indicate
that the conserved D123 residue is important not only for Nef-induced
CD4 and MHC-I downregulation, but also for the enhancement of viral
infectivity.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 5.
Mutation D123G in NefLai abolishes the ability of the
protein to enhance viral infectivity. (A) Comparison of infectivity.
HeLa cells were transiently transfected with pNL4-3wt,
pNL4-3 Nef, pNL4-3Nef4, or pNL4-3NefD123G proviral DNA. Infectious
virions were collected 48 h later and used immediately to infect
HeLa P4-2 indicator cells. Infectivity was evaluated by the number of
infected blue cells assayed, with different quantities of viruses
titrated by the p24 antigen content. These results are representative
of experiments performed with three different virus stocks. (B) Nef
protein expression in virus producer cells, estimated by Western
blotting of cell lysates with anti-Nef antibodies.
|
|
D123 residue required for formation of Nef dimers.
The
importance of the D123 residue for the biological activity of Nef could
be explained by its involvement in the interaction of the viral protein
with hTE. Alternatively, the crystal structure of Nef (2)
suggests that this residue may be critical for the formation of Nef
dimers (Fig. 6). We therefore
investigated whether mutation of the D123 residue in Nef affects its
ability to dimerize. Homodimers of NefLai in cellular lysates that were
denatured under reducing conditions in the presence of SDS have been
described before for nonfusion as well as CD8-Nef fusion proteins
(16, 30; O. T. Fackler, unpublished results).
Thus, hybrid CD8-Nef proteins were expressed in 293T cells, and the
cellular lysates were assayed for the presence of Nef dimers by Western
blotting. As shown in Fig. 7,
higher-molecular-weight species with an apparent molecular mass that
corresponds to that expected for homodimers were detected for the
wild-type Nef fusion protein (lane 3). In sharp contrast,
higher-molecular-weight species were detected neither for the
CD8NefD123V mutant fusion protein (lane 2) nor for the CD8T truncated
construct lacking intracellular residues and used as a control (lane
1). Given the similar expression levels of these Nef proteins, we
conclude that residue D123 is critical for the formation of Nef
homodimers.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
Localization of mutated residues within the Nef core
domain. (A) Secondary-structure representation of the conserved core
domain of HIV-1 Lai Nef, showing side chains of mutated residues. The
residues of which mutation disrupts interaction with hTE and
downregulation of CD4 are shown in blue. D123 is shown in dark blue.
All these residues (D108, D111, L112, F121, P122, and D123) are solvent
exposed in the monomer. Displayed on the secondary structure are the
SH3 binding PxxPxR motif (brown), the region involved in homomeric
contacts (yellow), and the putative CD4-binding surface (magenta). Note
that all mutated residues localize within the oligomer interface.
Dotted lines indicate where the unstructured N terminus (residues 1 to
70) and central loop region (residues 149 to 177) project out of the
Nef core domain. (B) Ribbon diagram of the Nef dimer. Colors are the
same as for panel A. Residue D123 is located at the bottom of the
interface and makes a salt bridge with residue R105 of the opposite
subunit.
|
|

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 7.
D123 is critical for dimerization of Nef. Immunoblot
analysis with anti-Nef monoclonal antibody 158 of total cell lysates of
293T cells expressing the CD8T (lane 1), CD8NefD123V (lane 2), and
CD8Nefwt (lane 3) fusion proteins.
|
|
 |
DISCUSSION |
In this study, by combining mutagenesis with protein interaction
and function studies, we identify a region of HIV-1 NefLai from
residues D108 to W124 which is required for Nef-mediated CD4
downregulation and for Nef-hTE interaction. In addition, we have shown
that the D123 residue in NefLai is critical not only for CD4
downregulation but also for two other essential functions of Nef, MHC-I
downregulation and enhancement of viral infectivity.
Site-directed mutagenesis has been used by several groups to define the
structural determinants required for Nef functions, and in general,
these different functions were linked to distinct structural
determinants in the core domain of the protein. The only motif
unequivocally known to be required for all functions of Nef was the
N-terminal myristoylated glycine, which is essential for the targeting
of this protein to the membrane. Our results suggest that besides this
N-terminal anchor domain, the conserved residue D123 in the core domain
of Nef is also involved in multiple functions of the protein.
The three-dimensional structure of the Nef protein, both alone and in
complex with Src family SH3 domains, has been solved (2, 24,
33). This structure consists of four antiparallel
-strands
flanked by two outer layers composed of a polyproline type II helix and
four
-helixes. All mutated residues reported herein localize on one
side of the core domain formed by
-helix B (residues Q104 to T117)
and the coil (residues Q118 to Q125), leading into
-strand A (Fig.
6A). The side chains of these mutated residues (except for W124) are
exposed to aqueous solvents on the tertiary structure of Nef. They may
therefore be available for interactions with cellular ligands.
Furthermore, the Nef D123 mutants, which have lost several Nef
functions and interaction with hTE, are still capable of binding to
several other Nef-binding proteins such as the µ1 chain (p47) of the
clathrin adaptor AP1 complex, the SH3 domain of Hck, and
-COP,
ruling out the possibility that the abrogation of different activities
of Nef by this mutation is due to alteration of the global structure of Nef.
The hypothesis has been raised that Nef could act as a connector
between the cellular endocytic machinery and the receptors whose
internalization and cellular trafficking are modified by Nef. As
recently reported, several cellular cofactors which could be required
for Nef-mediated CD4 and MHC-I downregulation are the medium chains of
clathrin-associated AP complexes and the
-COP subunit of the COP-I
complex (6, 20, 34, 36, 45, 46). Surprisingly, the mutants
carrying a mutation at position D123 described in this study, in spite
of complete deficiency for CD4 and MHC-I downregulation, still bind to
the µ1 chain and
-COP as efficiently as wild-type Nef. A
reasonable interpretation of these results is that binding of Nef to
the µ chains of AP complexes, as well as binding to
-COP, although
necessary, is not sufficient for Nef-induced receptor downregulation.
Thus, the D123 residue could be required for the interaction of Nef with its target receptors rather than with the endocytic machinery. From this point of view, it is of interest to note that this residue is
in the proximity of the putative CD4-binding site (residues 95 to 97, 106, and 109 to 110) mapped by Grzesiek et al. (23) (magenta
regions in Fig. 6).
The D123 residue is located close to a hydrophobic "spot" of the
surface of Nef, formed by residues L112, Y115, F121, and P122, which
has been reported to constitute the interface for oligomer formation by
Nef (2; S. Arold et al., unpublished results) (Fig.
6). Monomeric and oligomeric Nef molecules coexist in a
concentration-dependent equilibrium in solution (25;
Arold et al., unpublished results). L112, F121, and P122 form the
hydrophobic core of this interface, and D108 and D123 are important for
charge complementarity between Nef monomers. Nonconservative mutation of the D123 residue could destabilize or alter the oligomeric state of
Nef. Since this residue is also important for the interaction between
Nef and hTE, alteration of Nef oligomerization may explain why the D123
mutations affect both receptor downmodulation and binding to hTE.
Interestingly, in Nef oligomers but not in the Nef monomer, D123 is
interacting with the conserved diarginine motif R105-R106 of the
opposite protomer. Substitution of this RR motif leads to abrogation of
Nef-induced CD4 downregulation and enhancement of viral infectivity
(29, 60). R106 is also required for the interaction of Nef
with the Nef-associated kinase (40, 54, 60). A unifying
explanation for the numerous effects of the D123 substitution could
therefore be that this mutation affects both the oligomer interface of
Nef and the conformation of the RR motif. Indeed, the experiment shown
in Fig. 7 is in favor of a disruption of the oligomeric state of Nef
provoked by such a mutation. Nef oligomers have been reported by
several groups in vivo and in vitro (4, 16, 22, 31, 37), but their importance in Nef activities has not yet been elucidated. Our
results support the idea that oligomerization plays a critical role in
the different activities of the Nef protein. Since most receptors are
internalized as dimers, it is conceivable that homomeric interactions
between Nef molecules reinforce the interaction of Nef with an
oligomeric target, such as the CD4 dimer. It has also been reported
that the recognition of tyrosine-based endocytotic signals clearly
involves a dimeric µ2 chain of the clathrin adapter AP2 complex
(49).
The functional relevance of Nef-hTE interaction remains an open
question. While all the Nef mutations targeted in the region D108 to
W124 caused deficiency in both hTE binding and CD4 downregulation, suggesting a possible role of hTE binding in CD4 downregulation, the
importance of this interaction for Nef-mediated MHC-I downregulation and enhancement of virion infectivity is less clear, since some Nef
mutants (D108A and L112D) deficient in hTE binding are still able to
downregulate MHC-I and/or to enhance virion infectivity (G. Cohen,
personal communication). Thus, the loss of the three functions of Nef
observed with mutant D123 seems to be more specifically associated with
the loss of Nef oligomerization than with the lack of hTE interaction
resulting from this substitution.
The possible role of hTE in Nef-mediated CD4 downregulation could be
related to its TE enzymatic activity. As previously reported, the
preferred substrates of hTE are myristoyl-coenzyme A and
palmitoyl-coenzyme A (35). By releasing free myristate or
palmitate, TE activity could be indirectly involved in the control of
the lipid modifications of proteins, which are important for membrane
anchoring of proteins and receptor internalization. The observation
that Nef enhances in vitro hTE activity to cleave the TE bond of
palmitoyl-coenzyme A supports this hypothesis (59). Further
investigations are required to verify this possibility.
In this study, our attempt to map the hTE-binding site of Nef led to
identification of a conserved D123 residue which is critical for CD4
and MHC-I downregulation and enhancement of viral infectivity. This
residue is also important for Nef oligomerization. This suggests that
the oligomerization of Nef may be important for its functions.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from ANRS, Sidaction, ARC, and
Comité de Paris of the Ligue Nationale Contre le Cancer. L.X.L.
is supported by ANRS.
We thank George Cohen for his generous gift of Nef mutants, Isabelle
Bouchaert for expertise in FACS analysis, and Franck Letourneur for DNA sequencing.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Interactions
Moléculaires Hôte-Pathogène, INSERM U 529, ICGM, 24, Rue du Faubourg Saint-Jacques, 75014 Paris, France. Phone: (33) 1 44 41 25 65. Fax: (33) 1 44 41 23 99. E-mail:
benarous{at}cochin.inserm.fr.
 |
REFERENCES |
| 1.
|
Aiken, C.,
J. Konner,
N. R. Landau,
M. E. Lenburg, and D. Trono.
1994.
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.
Cell
76:853-864[CrossRef][Medline].
|
| 2.
|
Arold, S.,
P. Franken,
M. P. Strub,
F. Hoh,
S. Bénichou,
R. Benarous, and C. Dumas.
1997.
The crystal structures of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complexe in altered T cell receptor signaling.
Structure
15:1361-1372[CrossRef].
|
| 3.
|
Bachelerie, F.,
J. Alcami,
U. Hazan,
N. Israël,
B. Goud,
F. Arenzana-Seisdedos, and J. L. Virelizier.
1990.
Constitutive expression of human immunodeficiency virus (HIV) Nef protein in human astrocytes does not influence basal or induced HIV long terminal repeat activity.
J. Virol.
64:3059-3062[Abstract/Free Full Text].
|
| 4.
|
Barber, S. A.,
M. T. Flaherty,
S. M. Plafker, and J. E. Clements.
1998.
A novel kinase activity associated with Nef derived from neurovirulent simian immunodeficiency virus.
Virology
251:165-175[CrossRef][Medline].
|
| 5.
|
Baur, A. S.,
E. T. Sawai,
P. Dazin,
W. J. Fantl,
C. Cheng-Mayer, and B. M. Peterlin.
1994.
HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization.
Immunity
1:373-384[CrossRef][Medline].
|
| 6.
|
Bénichou, S.,
M. Bomsel,
M. Bodeus,
H. Durand,
M. Douté,
F. Letourneur,
J. Camonis, and R. Benarous.
1994.
Physical interaction of the HIV-1 Nef protein with beta-COP, a component of non-clathrin-coated vesicle for membrane traffic.
J. Biol. Chem.
269:30073-30076[Abstract/Free Full Text].
|
| 7.
|
Bouhamdan, M.,
S. Bénichou,
F. Rey,
J. M. Navarro,
I. Agostini,
B. Spire,
J. Camonis,
G. Slupphaug,
R. Vigne,
R. Benarous, and J. Sire.
1996.
Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme.
J. Virol.
70:697-704[Abstract].
|
| 8.
|
Chowers, M. Y.,
C. A. Spina,
T. J. Kwoh,
N. J. S. Fitch,
D. D. Richman, and J. C. Guatelli.
1994.
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.
J. Virol.
68:2906-2914[Abstract/Free Full Text].
|
| 9.
|
Clavel, F., and P. Charneau.
1994.
Fusion from without directed by human immunodeficiency virus particles.
J. Virol.
68:1179-1185[Abstract/Free Full Text].
|
| 10.
|
Collette, Y.,
H. Dutartre,
A. Benziane,
F. Ramos-Morales,
R. Benarous,
M. Harris, and D. Olive.
1996.
Physical and functional interaction of Nef with Lck.
J. Biol. Chem.
271:6333-6341[Abstract/Free Full Text].
|
| 11.
|
Craig, H. M.,
M. W. Pandori, and J. C. Guatelli.
1998.
Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 downregulation and optimal viral infectivity.
Proc. Natl. Acad. Sci. USA
95:11229-11234[Abstract/Free Full Text].
|
| 12.
|
Craig, H. M.,
M. W. Pandori,
N. L. Riggs,
D. D. Richman, and J. C. Guatelli.
1999.
Analysis of the SH3-binding region of HIV-1 nef: partial functional defects introduced by mutations in the polyproline helix and the hydrophobic pocket.
Virology
262:55-63[CrossRef][Medline].
|
| 13.
|
Cullen, B. R.
1998.
HIV-1 auxiliary proteins: making connections in a dying cell.
Cell
93:685-692[CrossRef][Medline].
|
| 14.
|
Drajic, T.,
U. Hazan, and M. Alizon.
1995.
Detection of cell fusion mediated by the envelopes of human retroviruses by transactivation of a reporter gene.
Methods Mol. Genet.
7:218-236.
|
| 15.
|
Du, Z.,
S. M. Lang,
V. G. Sasseville,
A. A. Lackner,
P. O. Ilyinskii,
M. D. Daniel,
J. U. Jung, and R. C. Desrosiers.
1995.
Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys.
Cell
82:665-674[CrossRef][Medline].
|
| 16.
|
Fackler, O. T.,
N. Kienzle,
E. Kremmer,
A. Boese,
B. Schramm,
T. Klimkait,
C. Kucherer, and N. Mueller-Lantzsch.
1997.
Association of human immunodeficiency virus Nef protein with actin is myristoylation dependent and influences its subcellular localization.
Eur. J. Biochem.
247:843-851[Medline].
|
| 17.
|
Fackler, O. T.,
W. Luo,
M. Geyer,
A. S. Alberts, and B. M. Peterlin.
1999.
Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions.
Mol. Cell
3:729-739[CrossRef][Medline].
|
| 18.
|
Fujii, Y.,
K. Otake,
M. Tashiro, and A. Adachi.
1996.
Human immunodeficiency virus type 1 nef protein on the cell surface is cytocidal for human CD4+ T cells.
FEBS Lett.
393:105-108[CrossRef][Medline].
|
| 19.
|
Goldsmith, M. A.,
M. T. Warmerdam,
R. E. Atchison,
M. D. Miller, and W. C. Greene.
1995.
Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef.
J. Virol.
69:4112-4121[Abstract].
|
| 20.
|
Greenberg, M. E.,
S. Bronson,
M. Lock,
M. Neumann,
G. N. Pavlakis, and J. Skowronski.
1997.
Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation.
EMBO J.
16:6964-6976[CrossRef][Medline].
|
| 21.
|
Greenberg, M. E.,
A. J. Iafrate, and J. Skowronski.
1998.
The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class 1 MHC complexes.
EMBO J.
17:2777-2789[CrossRef][Medline].
|
| 22.
|
Greenway, A.,
A. Azad, and D. McPhe.
1995.
Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines.
J. Virol.
69:1842-1850[Abstract].
|
| 23.
|
Grzesiek, S.,
S. J. Stahl,
P. T. Wingfield, and A. Bax.
1996.
The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef mapping of the Nef binding surface by NMR.
Biochemistry
35:10256-10261[CrossRef][Medline].
|
| 24.
|
Grzesiek, S.,
A. Bax,
G. M. Clore,
A. M. Gronenborn,
J. S. Hu,
J. Kaufman,
I. Palmer,
S. J. Stahl, and P. T. Wingfield.
1996.
The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase.
Nat. Struct. Biol.
3:340-345[CrossRef][Medline].
|
| 25.
|
Grzesiek, S.,
A. Bax,
J. S. Hu,
J. Kaufman,
I. Palmer,
S. J. Stahl, and P. T. Wingfield.
1997.
Refined solution structure and backbone dynamics of HIV-1 Nef.
Protein Sci.
6:1248-1263[Abstract].
|
| 26.
|
Harris, M.
1999.
HIV: a new role for Nef in the spread of HIV.
Curr. Biol.
9:R459-R461[Medline].
|
| 27.
|
Harris, M. P. G., and J. C. Neil.
1994.
Myristoylation-dependent binding of HIV-1 Nef to CD4.
J. Mol. Biol.
241:136-142[CrossRef][Medline].
|
| 28.
|
Howe, A. Y.,
J. U. Jung, and R. C. Derosiers.
1998.
Zeta chain of the T-cell receptor interacts with Nef of simian immunodeficiency virus and human immunodeficiency virus type 2.
J. Virol.
72:9827-9834[Abstract/Free Full Text].
|
| 29.
|
Iafrate, A. J.,
S. Bronson, and J. Skowronski.
1997.
Separable functions of Nef disrupt two aspects of T cell receptor machinery: CD4 expression and CD3 signaling.
EMBO J.
16:673-684[CrossRef][Medline].
|
| 30.
|
Kestler, H. W.,
D. J. Ringler,
K. Mori,
D. L. Panicali,
P. K. Sehgal,
M. D. Daniel, and R. Desrosiers.
1991.
Importance of the nef gene for maintenance of high virus loads and for development of AIDS.
Cell
65:651-662[CrossRef][Medline].
|
| 31.
|
Kienzle, N.,
J. Freund,
H. R. Kalbitzer, and N. Mueller-Lantzsch.
1993.
Oligomerization of the Nef protein from human immunodeficiency virus (HIV) type 1.
Eur. J. Biochem.
214:451-457[Medline].
|
| 32.
|
Lama, J.,
A. Mangasarian, and D. Trono.
1999.
Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner.
Curr. Biol.
9:622-631[CrossRef][Medline].
|
| 33.
|
Lee, C. H.,
K. Saksela,
U. A. Mirza,
B. T. Chait, and J. Kuriyan.
1996.
Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain.
Cell
85:931-942[CrossRef][Medline].
|
| 34.
|
Le Gall, S.,
L. Erdtmann,
S. Bénichou,
C. Berlioz-Torrente,
L. X. Liu,
R. Benarous,
J. M. Heard, and O. Schwartz.
1998.
Nef interacts with the µ subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules.
Immunity
8:483-495[CrossRef][Medline].
|
| 35.
|
Liu, L. X.,
F. Margottin,
S. Le Gall,
O. Schwartz,
L. Selig,
R. Benarous, and S. Bénichou.
1997.
Binding of HIV-1 Nef to a novel thioesterase enzyme correlates with Nef-mediated CD4 down-regulation.
J. Biol. Chem.
272:13779-13785[Abstract/Free Full Text].
|
| 36.
|
Lock, M.,
M. E. Greenberg,
A. J. Iafrate,
T. Swigut,
J. Muench,
F. Kirchhoff,
N. Shohdy, and J. Skowronski.
1999.
Two elements target SIV Nef to the AP-2 clathrin adaptor complex, but only one is required for the induction of CD4 endocytosis.
EMBO J.
18:2722-2733[CrossRef][Medline].
|
| 37.
|
Luo, T.,
J. L. Foster, and J. V. Garcia.
1997.
Molecular determinants of Nef function.
J. Biomed. Sci.
4:132-138[CrossRef][Medline].
|
| 38.
|
Mangasarian, A.,
M. Foti,
C. Aiken,
D. Chin,
J. L. Carpentier, and D. Trono.
1997.
The HIV-1 Nef protein acts as a connector with sorting pathways in the Golgi and at the plasma membrane.
Immunity
6:67-77[CrossRef][Medline].
|
| 39.
|
Mangasarian, A.,
V. Piguet,
J. K. Wang,
Y. L. Chen, and D. Trono.
1999.
Nef-induced CD4 and major histocompatibility complex class I (MHC-I) downregulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking.
J. Virol.
73:1964-1973[Abstract/Free Full Text].
|
| 40.
|
Manninen, A.,
M. Hiipakka,
M. Vihinen,
W. Lu,
B. J. Mayer, and K. Saksela.
1998.
SH3-domain binding function of HIV-1 Nef is required for association with a PAK-related kinase.
Virology
250:273-282[CrossRef][Medline].
|
| 41.
|
Miller, M. D.,
M. T. Warmerdam,
I. Gaston,
W. C. Greene, and M. B. Feinberg.
1994.
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.
J. Exp. Med.
179:101-113[Abstract/Free Full Text].
|
| 42.
|
Moarefi, I.,
M. Lafevre-Bernst,
F. Sicheri,
M. Huse,
C. H. Lee,
J. Kuriyan, and W. T. Miller.
1997.
Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement.
Nature
385:650-653[CrossRef][Medline].
|
| 43.
|
Nunn, M. F., and J. W. Marsh.
1996.
Human immunodeficiency virus type 1 Nef associates with a member of the p21-activated kinase family.
J. Virol.
70:6157-6161[Abstract].
|
| 44.
|
Owen, D. J., and P. R. Evans.
1998.
A structural explanation for the recognition of tyrosine-based endocytic signals.
Science
282:1327-1332[Abstract/Free Full Text].
|
| 45.
|
Piguet, V.,
Y. L. Chen,
A. Mangasarian,
M. Foti,
J. L. Carpentier, and D. Trono.
1998.
Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes.
EMBO J.
17:2472-2481[CrossRef][Medline].
|
| 46.
|
Piguet, V.,
F. Gu,
M. Foti,
N. Demaurex,
J. Gruenberg,
J. L. Carpentier, and D. Trono.
1999.
Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes.
Cell
97:63-73[CrossRef][Medline].
|
| 47.
|
Piguet, V.,
S. Le Gall,
O. Schwartz, and D. Trono.
1999.
The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors.
Immunol. Rev.
168:51-63[CrossRef][Medline].
|
| 48.
|
Piguet, V., and D. Trono.
1999.
The Nef protein of primate lentiviruses.
Rev. Med. Virol.
9:111-120[CrossRef][Medline].
|
| 49.
|
Riggs, N. L.,
H. M. Craig,
M. W. Pandori, and J. C. Guatelli.
1999.
The dileucine-based sorting motif in HIV-1 Nef is not required for down-regulation of class I MHC.
Virology
258:203-207[CrossRef][Medline].
|
| 50.
|
Ross, T. M.,
A. E. Oran, and B. R. Cullen.
1999.
Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the Nef Protein.
Curr. Biol.
9:613-621[CrossRef][Medline].
|
| 51.
|
Rossi, F.,
A. Gallina, and G. Milanesi.
1996.
Nef-CD4 physical interaction sensed with the yeast two-hybrid system.
Virology
217:397-403[CrossRef][Medline].
|
| 52.
|
Saksela, K.,
G. Cheng, and D. Baltimore.
1995.
Proline-rich (PxxP) motifs in HIV-1 nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4.
EMBO J.
14:484-491[Medline].
|
| 53.
|
Sawai, E. T.,
A. Baur,
H. Struble,
B. M. Peterlin,
J. A. Levy, and C. Cheng-Mayer.
1994.
Human immunodeficiency virus type 1 Nef associated with a cellular serine kinase in T lymphocytes.
Proc. Natl. Acad. Sci. USA
91:1539-1543[Abstract/Free Full Text].
|
| 54.
|
Sawai, E. T.,
A. S. Baur,
B. M. Peterlin,
J. A. Levy, and C. Cheng-Mayer.
1995.
A conserved domain and membrane targeting of Nef from HIV and SIV are required for association with a cellular serine kinase activity.
J. Biol. Chem.
270:15307-15314[Abstract/Free Full Text].
|
| 55.
|
Schwartz, O.,
V. Marechal,
S. Le Gall,
F. Lemonnier, and J. M. Heard.
1996.
Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.
Nat. Med.
2:338-342[CrossRef][Medline].
|
| 56.
|
Shugars, D. C.,
M. S. Smith,
D. H. Glueck,
P. V. Nantermet,
F. Seillier-Moiseiwitsch, and R. Swanstrom.
1993.
Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo.
J. Virol.
67:4639-4650[Abstract/Free Full Text].
|
| 57.
|
Skowronski, J.,
D. Parks, and R. Mariani.
1993.
Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene.
EMBO J.
12:703-713[Medline].
|
| 58.
|
Swingler, S.,
P. Gallay,
D. Camaur,
J. Song,
A. Abo, and D. Trono.
1997.
The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix.
J. Virol.
71:4372-4377[Abstract].
|
| 59.
|
Watanabe, H.,
T. Shiratori,
H. Shoji,
S. Miyatake,
Y. Okazaki,
K. Ikuta,
T. Sato, and T. Saito.
1997.
A novel acyl-CoA thioesterase enhances its enzymatic activity by direct binding with HIV Nef.
Biochem. Biophys. Res. Commun.
238:234-239[CrossRef][Medline].
|
| 60.
|
Wiskerchen, M., and C. Cheng-Mayer.
1996.
HIV-1 Nef association with cellular serine kinase correlates with enhanced virion infectivity and efficient proviral DNA synthesis.
Virology
224:292-301[CrossRef][Medline].
|
| 61.
|
Xu, X. N.,
B. Laffert,
G. R. Screaton,
M. Kraft,
D. Wolf,
W. Kolanus,
J. Mongkolsapay,
A. J. McMichael, and A. S. Baur.
1999.
Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor chain.
J. Exp. Med.
189:1489-1496[Abstract/Free Full Text].
|
Journal of Virology, June 2000, p. 5310-5319, Vol. 74, No. 11
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lu, T.-c., He, J. C., Wang, Z.-h., Feng, X., Fukumi-Tominaga, T., Chen, N., Xu, J., Iyengar, R., Klotman, P. E.
(2008). HIV-1 Nef Disrupts the Podocyte Actin Cytoskeleton by Interacting with Diaphanous Interacting Protein. J. Biol. Chem.
283: 8173-8182
[Abstract]
[Full Text]
-
Wonderlich, E. R., Williams, M., Collins, K. L.
(2008). The Tyrosine Binding Pocket in the Adaptor Protein 1 (AP-1) {micro}1 Subunit Is Necessary for Nef to Recruit AP-1 to the Major Histocompatibility Complex Class I Cytoplasmic Tail. J. Biol. Chem.
283: 3011-3022
[Abstract]
[Full Text]
-
Pizzato, M., Helander, A., Popova, E., Calistri, A., Zamborlini, A., Palu, G., Gottlinger, H. G.
(2007). Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc. Natl. Acad. Sci. USA
104: 6812-6817
[Abstract]
[Full Text]
-
Crotti, A., Neri, F., Corti, D., Ghezzi, S., Heltai, S., Baur, A., Poli, G., Santagostino, E., Vicenzi, E.
(2006). Nef Alleles from Human Immunodeficiency Virus Type 1-Infected Long-Term-Nonprogressor Hemophiliacs with or without Late Disease Progression Are Defective in Enhancing Virus Replication and CD4 Down-Regulation. J. Virol.
80: 10663-10674
[Abstract]
[Full Text]
-
Vincent, P., Priceputu, E., Kay, D., Saksela, K., Jolicoeur, P., Hanna, Z.
(2006). Activation of p21-activated Kinase 2 and Its Association with Nef Are Conserved in Murine Cells but Are Not Sufficient to Induce an AIDS-like Disease in CD4C/HIV Transgenic Mice. J. Biol. Chem.
281: 6940-6954
[Abstract]
[Full Text]
-
O'Neill, E., Kuo, L. S., Krisko, J. F., Tomchick, D. R., Garcia, J. V., Foster, J. L.
(2006). Dynamic Evolution of the Human Immunodeficiency Virus Type 1 Pathogenic Factor, Nef. J. Virol.
80: 1311-1320
[Abstract]
[Full Text]
-
Cluet, D., Bertsch, C., Beyer, C., Gloeckler, L., Erhardt, M., Gut, J.-P., Galzi, J.-L., Aubertin, A.-M.
(2005). Detection of Human Immunodeficiency Virus Type 1 Nef and CD4 Physical Interaction in Living Human Cells by Using Bioluminescence Resonance Energy Transfer. J. Virol.
79: 8629-8636
[Abstract]
[Full Text]
-
Madrid, R., Janvier, K., Hitchin, D., Day, J., Coleman, S., Noviello, C., Bouchet, J., Benmerah, A., Guatelli, J., Benichou, S.
(2005). Nef-induced Alteration of the Early/Recycling Endosomal Compartment Correlates with Enhancement of HIV-1 Infectivity. J. Biol. Chem.
280: 5032-5044
[Abstract]
[Full Text]
-
Kirchhoff, F., Schindler, M., Bailer, N., Renkema, G. H., Saksela, K., Knoop, V., Muller-Trutwin, M. C., Santiago, M. L., Bibollet-Ruche, F., Dittmar, M. T., Heeney, J. L., Hahn, B. H., Munch, J.
(2004). Nef Proteins from Simian Immunodeficiency Virus-Infected Chimpanzees Interact with p21-Activated Kinase 2 and Modulate Cell Surface Expression of Various Human Receptors. J. Virol.
78: 6864-6874
[Abstract]
[Full Text]
-
Alexander, M., Bor, Y.-c., Ravichandran, K. S., Hammarskjold, M.-L., Rekosh, D.
(2004). Human Immunodeficiency Virus Type 1 Nef Associates with Lipid Rafts To Downmodulate Cell Surface CD4 and Class I Major Histocompatibility Complex Expression and To Increase Viral Infectivity. J. Virol.
78: 1685-1696
[Abstract]
[Full Text]
-
Stove, V., Naessens, E., Stove, C., Swigut, T., Plum, J., Verhasselt, B.
(2003). Signaling but not trafficking function of HIV-1 protein Nef is essential for Nef-induced defects in human intrathymic T-cell development. Blood
102: 2925-2932
[Abstract]
[Full Text]
-
Williams, M., Roeth, J. F., Kasper, M. R., Fleis, R. I., Przybycin, C. G., Collins, K. L.
(2002). Direct Binding of Human Immunodeficiency Virus Type 1 Nef to the Major Histocompatibility Complex Class I (MHC-I) Cytoplasmic Tail Disrupts MHC-I Trafficking. J. Virol.
76: 12173-12184
[Abstract]
[Full Text]
-
Lundquist, C. A., Tobiume, M., Zhou, J., Unutmaz, D., Aiken, C.
(2002). Nef-Mediated Downregulation of CD4 Enhances Human Immunodeficiency Virus Type 1 Replication in Primary T Lymphocytes. J. Virol.
76: 4625-4633
[Abstract]
[Full Text]
-
Janvier, K., Craig, H., Le Gall, S., Benarous, R., Guatelli, J., Schwartz, O., Benichou, S.
(2001). Nef-Induced CD4 Downregulation: a Diacidic Sequence in Human Immunodeficiency Virus Type 1 Nef Does Not Function as a Protein Sorting Motif through Direct Binding to {beta}-COP. J. Virol.
75: 3971-3976
[Abstract]
[Full Text]
-
Manninen, A., Huotari, P., Hiipakka, M., Renkema, G. H., Saksela, K.
(2001). Activation of NFAT-Dependent Gene Expression by Nef: Conservation among Divergent Nef Alleles, Dependence on SH3 Binding and Membrane Association, and Cooperation with Protein Kinase C-{theta}. J. Virol.
75: 3034-3037
[Abstract]
[Full Text]
-
Doms, R. W., Trono, D.
(2000). The plasma membrane as a combat zone in the HIV battlefield. Genes Dev.
14: 2677-2688
[Full Text]
-
Yang, S., Sun, Y., Zhang, H.
(2001). The Multimerization of Human Immunodeficiency Virus Type I Vif Protein. A REQUIREMENT FOR Vif FUNCTION IN THE VIRAL LIFE CYCLE. J. Biol. Chem.
276: 4889-4893
[Abstract]
[Full Text]
-
Hunt, M. C., Solaas, K., Kase, B. F., Alexson, S. E. H.
(2002). Characterization of an Acyl-CoA Thioesterase That Functions as a Major Regulator of Peroxisomal Lipid Metabolism. J. Biol. Chem.
277: 1128-1138
[Abstract]
[Full Text]